abstract |
There are presented compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein YYXXX3 and R are as described in this application. These compounds are believed to inhibit MDM2-p53 interaction and as such the compounds will have anti-hyperproliferative cellular activity. |